PT-141 (Bremelanotide)

Also referred to as Bremelanotide, Vyleesi.

Status: FDA-approved for a specific indication. This is one of the easiest categories to misread. Bremelanotide is FDA-approved as Vyleesi for a narrowly defined condition in premenopausal women only. Material sold generically online as PT-141, including research-market or compounded versions, is not the approved Vyleesi product, and approval of Vyleesi does not transfer to it. Approval likewise does not extend to men or to postmenopausal women under any product name.

PT-141 is the research name for bremelanotide, a melanocortin receptor agonist, and it exists in two very different forms that patients frequently conflate. One form, marketed under the brand name Vyleesi, is FDA-approved specifically for acquired, generalized hypoactive sexual desire disorder in premenopausal women. The other, sold on the research market as PT-141, is not the approved Vyleesi product, is not FDA-approved for any use, and is not the same as a compounded preparation supervised by a pharmacist. Approval does not extend to men or to postmenopausal women under either name, and understanding this distinction is essential before considering any use.

What it is

Bremelanotide is a synthetic peptide analog of alpha-melanocyte-stimulating hormone that acts on melanocortin receptors, including MC4R, which has been studied in relation to sexual desire pathways in the brain. Vyleesi is the specific FDA-approved autoinjector formulation of this molecule, manufactured under pharmaceutical quality controls. Material labeled PT-141 sold outside that approved supply chain, including research-market vials or compounded preparations, is chemically related but is not manufactured, tested, or regulated as the approved Vyleesi product.

Why people ask about it

Patients ask about PT-141 because it circulates widely under that research name in online and grey-market channels, often with claims that extend well beyond the narrow population the approved product was studied in. Some ask specifically because they have heard about Vyleesi and want to understand whether the two names refer to the same regulated product. Others, including men and postmenopausal women, ask about it for sexual-health purposes that fall outside the approved indication entirely.

Proposed mechanism

Bremelanotide is proposed to act on melanocortin 4 receptors in the central nervous system, a pathway studied for its role in modulating sexual desire independent of hormonal or vascular mechanisms used by other sexual-health medications. This mechanism is supported by the clinical trial program that led to Vyleesi's approval in premenopausal women with acquired, generalized hypoactive sexual desire disorder. The same proposed mechanism has been extended in smaller or less rigorous studies to other populations, including men, but that extension has not produced an approved indication.

What researchers have studied

The clinical trial program supporting Vyleesi's approval for hypoactive sexual desire disorder in premenopausal women
Melanocortin receptor pharmacology and its proposed role in central sexual arousal pathways
Smaller studies exploring bremelanotide in men, which have not led to an approved indication
Investigational interest in melanocortin agonists for erectile dysfunction, studied separately from the approved female indication
Post-marketing safety monitoring of Vyleesi, including blood pressure and nausea-related effects

Human evidence

Randomized controlled trials supporting Vyleesi's approval were conducted specifically in premenopausal women with acquired, generalized hypoactive sexual desire disorder.
Evidence in men remains limited to smaller or earlier-phase studies that have not led to an approved indication for that population.
Evidence in postmenopausal women has not supported an approved indication for that population either.
Research-market PT-141 products have not undergone the same clinical evaluation as the approved Vyleesi formulation, so trial results for Vyleesi cannot be assumed to apply to those products.

Preclinical evidence

Animal studies describe melanocortin receptor activation in brain regions associated with sexual behaviour.
Receptor-binding studies characterize bremelanotide's affinity for MC4R relative to other melanocortin receptor subtypes.
Early pharmacology studies in animal models informed the dose-finding work that preceded human trials of the approved product.

What is not yet known

Whether bremelanotide has a reliable, clinically meaningful effect in men, since this has not been established through an approved indication.
Long-term safety of repeated use beyond the trial periods that supported Vyleesi's approval.
What quality, purity, or dosing accuracy exists in research-market PT-141 products sold outside the approved supply chain.
Whether a compounded bremelanotide preparation carries the same safety profile as the approved Vyleesi product, since it has not been evaluated the same way.
How melanocortin receptor activation interacts with other cardiovascular or psychiatric conditions outside the studied population.

Regulatory status and access

Vyleesi is the specific FDA-approved formulation of bremelanotide and is available only through the regulatory pathway that governs an approved prescription drug. A compounded preparation labeled PT-141 or bremelanotide is a different product from Vyleesi, is not FDA-approved, and compounding is never a form of FDA approval. Ask about current availability. Only a physician can determine whether a conversation about approved or non-approved options is appropriate after an evaluation.

Known and potential risks

Reported effects associated with bremelanotide use include nausea and transient increases in blood pressure, which is part of why the approved product carries specific prescribing guidance.
Research-market PT-141 carries unregulated grey-market quality risk, including uncertain purity, sterility, and actual peptide content, since it has not been manufactured under pharmaceutical quality controls.
Using a non-approved PT-141 product outside the studied population, including men or postmenopausal women, means the safety and effectiveness data from the approved trials do not apply.
Cardiovascular risk factors may be relevant given blood-pressure effects observed with the approved formulation.
Overlapping use with other medications affecting blood pressure or the central nervous system has not been fully characterized outside the approved trial population.

Cautions and who may not be a candidate

Uncontrolled hypertension or significant cardiovascular disease, given the blood-pressure effects associated with bremelanotide.
Men and postmenopausal women, populations outside the approved indication where safety and effectiveness data are limited.
Pregnancy or breastfeeding, where bremelanotide has not been established as appropriate.
Undiagnosed sexual-desire concerns that may have another underlying medical or psychiatric cause requiring separate evaluation.
Use of a non-approved, research-market, or compounded product without physician oversight and product-quality verification.

Questions to discuss with a physician

Am I in the population that Vyleesi is actually approved for?
What is the difference between the approved Vyleesi product and material sold online as PT-141?
What cardiovascular or blood pressure factors would be relevant before considering this medication?
What does the evidence show, and not show, for populations outside the approved indication?
How would a physician evaluate whether an approved option is appropriate for my situation?
What are the quality risks of a research-market or compounded bremelanotide product?

Frequently asked questions

Is PT-141 FDA-approved?

The specific formulation sold as Vyleesi is FDA-approved for acquired, generalized hypoactive sexual desire disorder in premenopausal women only. Material sold generically online as PT-141 is not that approved product.

Does GOAL.MD sell PT-141?

This page is educational only and describes regulatory status rather than an offer to sell. It is not a substitute for an individualized medical evaluation.

Is PT-141 the same thing as Vyleesi?

PT-141 is the research name for the molecule bremelanotide. Vyleesi is the specific FDA-approved product built on that molecule. Research-market material labeled PT-141 is not manufactured or regulated as Vyleesi.

Can men use PT-141?

The approved indication for Vyleesi applies only to premenopausal women with a specific diagnosis. Approval does not extend to men, and studies in men have not led to an approved product.

Can postmenopausal women use PT-141?

No. The approved indication is limited to premenopausal women, and it does not extend to postmenopausal women.

Is a compounded version of bremelanotide the same as Vyleesi?

No. A compounded preparation is not the approved Vyleesi product, and compounding is never a form of FDA approval, regardless of the chemical similarity.

What condition is Vyleesi approved to address?

It is approved specifically for acquired, generalized hypoactive sexual desire disorder in premenopausal women, a defined diagnosis rather than a general low-libido complaint.

What are the known effects associated with bremelanotide?

Nausea and transient blood pressure increases have been reported in association with the approved product, which is part of why cardiovascular history matters in a physician evaluation.

Why is research-market PT-141 considered risky?

It is not manufactured under the same quality controls as the approved Vyleesi product, so purity, sterility, and actual content cannot be assumed, and safety data from approved trials do not apply to it.

Does bremelanotide work the same way as other sexual-health medications?

It is proposed to act through melanocortin receptor signalling in the central nervous system, a different pathway from vascular-acting medications used for other sexual-health conditions.

Is acquired, generalized hypoactive sexual desire disorder the same as general low libido?

No. It is a specific clinical diagnosis with defined criteria, and it is distinct from situational or general changes in sexual interest, which may have other causes.

This page is educational. Nothing here can be ordered, and nothing here is a prescription or medical advice. Compounded preparations are not FDA-approved. To ask about current availability, visit goal.md/peptides/connect or call or text 314-907-3103.

Medically reviewed by Michael Fitch, MD, MD. Last reviewed 2026-08-13.